Introduction of NICE’s health technology assessment in UK and enlightenment to the dynamic adjustment of Chinese medical insurance directory_Chinese Journal of Evidence-Based Medicine

Authors：

YAO Jiaqi , ZHOU Ting , GUAN Xin ,  MA Aixia

School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, 211198, P.R.China;

Corresponding author：

MA Aixia, Email: aixiama73@126.com

Keywords：

Health technology assessment; The national institute for health and care excellence; Health insurance directory selection; Medical insurance directory dynamic adjustment

DOI：

10.7507/1672-2531.201804116

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

This paper used the application of health technology assessment (HTA) in medical insurance directory adjustment as an example, introduced NICE’s HTA in UK from seeking legislative support for HTA, established the system of HTA, improved the process of HTA and increasing awareness of using HTA among decision-maker, and provided suggestions for the development and advancement of HTA in China.

Citation： YAO Jiaqi, ZHOU Ting, GUAN Xin, MA Aixia. Introduction of NICE’s health technology assessment in UK and enlightenment to the dynamic adjustment of Chinese medical insurance directory. Chinese Journal of Evidence-Based Medicine, 2018, 18(9): 984-989. doi: 10.7507/1672-2531.201804116 Copy

1.	OECD. Health expenditure and financing. Available at: http://stats.oecd.org/Index.aspx?DataSetCode.
2.	Babar Z. Pharmaceutical Prices in the 21st Century. Adis, Cham, 2015.
3.	Department of Health. Report of The Triennial Review for The National Institute For Health And Care Excellence. London: Department of Health, 2015.
4.	Department of Health. The Pharmaceutical Price Regulation Scheme Eleventh Report to Parliament. 2012.
5.	NICE. Technology appraisal decisions. Available at: https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance.
6.	Brockis E. A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications, 2016.
7.	NICE. Fast track appraisal. 2017.
8.	NICE. Guide to the methods of technology appraisal, 2013.
9.	NICE. Technology appraisal guidance: Summary of decisions. 2017.
10.	Kaltenthaler E, Papaioannou D, Boland A, et al. The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years. Value Health, 2011, 14(8): 1158-1165.
11.	NICE. Guide to the processes of technology appraisal, 2014.
12.	Salas-Vega S, Bertling A, Mossialos E. A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK. Health Policy, 2016, 120(10): 1104-1114.
13.	NICE. Guide to the technology appraisal and highly specialized technologies appeal process, 2017.
14.	NICE. Guide to the single technology appraisal process, 2012.
15.	Oortwijn W. The role of health technology assessment in selected middle-income countries/regions. Beijing: CNHDRC, 2011.
16.	隋宾艳, 齐雪然. 英国NICE卫生技术评估研究决策转化机制及对我国的启示. 中国卫生政策研究, 2015, 8(7): 74-78.
17.	卫生计生委. 关于加强卫生与健康科技成果转移转化工作的指导意见. 国卫科教发[2016] 51号, 2016.
18.	医疗保险司. 关于公开征求建立完善基本医疗保险、工伤保险和生育保险药品目录动态调整机制有关意见议的通知, 2017.

1. OECD. Health expenditure and financing. Available at: http://stats.oecd.org/Index.aspx?DataSetCode.
2. Babar Z. Pharmaceutical Prices in the 21st Century. Adis, Cham, 2015.
3. Department of Health. Report of The Triennial Review for The National Institute For Health And Care Excellence. London: Department of Health, 2015.
4. Department of Health. The Pharmaceutical Price Regulation Scheme Eleventh Report to Parliament. 2012.
5. NICE. Technology appraisal decisions. Available at: https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance.
6. Brockis E. A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications, 2016.
7. NICE. Fast track appraisal. 2017.
8. NICE. Guide to the methods of technology appraisal, 2013.
9. NICE. Technology appraisal guidance: Summary of decisions. 2017.
10. Kaltenthaler E, Papaioannou D, Boland A, et al. The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years. Value Health, 2011, 14(8): 1158-1165.
11. NICE. Guide to the processes of technology appraisal, 2014.
12. Salas-Vega S, Bertling A, Mossialos E. A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK. Health Policy, 2016, 120(10): 1104-1114.
13. NICE. Guide to the technology appraisal and highly specialized technologies appeal process, 2017.
14. NICE. Guide to the single technology appraisal process, 2012.
15. Oortwijn W. The role of health technology assessment in selected middle-income countries/regions. Beijing: CNHDRC, 2011.
16. 隋宾艳, 齐雪然. 英国NICE卫生技术评估研究决策转化机制及对我国的启示. 中国卫生政策研究, 2015, 8(7): 74-78.
17. 卫生计生委. 关于加强卫生与健康科技成果转移转化工作的指导意见. 国卫科教发[2016] 51号, 2016.
18. 医疗保险司. 关于公开征求建立完善基本医疗保险、工伤保险和生育保险药品目录动态调整机制有关意见议的通知, 2017.

Previous Article
Analysis of different dimensions and related factors of compliance of clinical researchers
Next Article
Establishment of quality criteria for clinical nursing practice guidelines in China

Chinese Journal of Evidence-Based Medicine

Introduction of NICE’s health technology assessment in UK and enlightenment to the dynamic adjustment of Chinese medical insurance directory

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content